Engflag

Brismucol

Quick links to important sections

Brismucol

Brismucol_EN

Method of action: Antitussive, Cough And Cold Preparations, Expectorant, Increasing The Production Of Surfactant, Mucolytic, Secretolitic, Secretory

Treatment option: Asthma, Bronchitis, Respiratory Tract Disease, Laryngitis, Pneumonia, Rhinitis, Chronic Obstructive Lung Disease

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Brismucol

Property Description
Active ingredient Ambroxol hydrochloride
Form Tablets, Syrup, Oral Solution, Prolonged-release capsules
Pharmacological class Mucolytic and Secretolytic agent
Common purpose Facilitating the expulsion of thick mucus (phlegm)
Origin Synthetic, derived from Bromhexine

Brismucol is a synthetic pharmaceutical preparation featuring the active ingredient Ambroxol hydrochloride, which is classified as a mucolytic agent and an expectorant. This substance is characterized by its ability to act directly upon the consistency of respiratory tract secretions. Ambroxol is chemically derived from the related compound bromhexine, existing as a refined metabolite engineered to provide a more specific and targeted action within the airways. This synthetic origin ensures a distinct and predictable pharmacological profile, setting it apart from older, natural-source agents.

Composition, Forms, and General Purpose

The medication is a single-ingredient product, whose efficacy is concentrated solely on Ambroxol hydrochloride. This active substance is clinically recognized for its action in enhancing airway fluidity. Brismucol is commonly available for oral administration in several core pharmaceutical preparations, including conventional solid tablets and patient-friendly liquid forms such as syrup and oral solution. Furthermore, specialized dosage formats like inhalable solution and prolonged-release capsules are also manufactured to accommodate different clinical needs and durations of effect. The substance is known for its ability to break down acidic mucopolysaccharides, which are components of thick mucus. The overarching goal of the compound is to facilitate the efficient expulsion of thick, overly viscous mucus, often used in a typical scenario to address the discomfort associated with a wet, congested cough. This process is integral to restoring normal function and supporting the patient’s ability to breathe freely.

What side effects are possible with Brismucol?

Possible Side Effects and Safety Information

The safety profile of Ambroxol hydrochloride (Brismucol) is documented in official government regulatory texts, which classify adverse reactions based on frequency and affected system-organ classes.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to standard regulatory tiers:

  • Common (ge 1/100 to < 1/10): Include effects on the gastrointestinal tract and nervous system such as nausea, dysgeusia (taste disturbance), and oral/pharyngeal hypoesthesia (numbness in the mouth or throat).
  • Uncommon (ge 1/1,000 to < 1/100): Include vomiting, diarrhoea, dyspepsia, abdominal pain, and pyrexia (fever).
  • Rare (ge 1/10,000 to < 1/1,000): Hypersensitivity reactions, rash, and urticaria.

Serious Safety Considerations

The most significant, though rare, safety considerations documented in regulatory sources involve severe reactions classified under Immune System and Skin Disorders.

  • Anaphylactic Reactions and Shock are documented as potential, immediate, severe hypersensitivity events.
  • Severe Cutaneous Adverse Reactions (SCARs): The regulatory profile explicitly notes the risk of rare, serious skin conditions, including Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN), and Erythema multiforme.

Population and Concomitant Use Constraints

Official labeling defines specific constraints for certain populations and uses:

  • Renal and Hepatic Function: Caution is advised in individuals with impaired renal function or severe hepatic disease, as the elimination of the active substance’s metabolites may be reduced.
  • Peptic Ulcers: Use requires caution in patients with a history of peptic ulcers due to the drug's effect on mucosal barriers.
  • Antitussive Agents: The official safety profile notes that co-administration with certain cough-suppressant agents is generally not recommended due to the potential for secretions to accumulate.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with this medication, whether from a single large ingestion or from cumulative use of multiple products containing the same active ingredient, carries a significant risk of severe, potentially fatal acute liver failure (hepatic necrosis). Due to the nature of this risk, immediate medical evaluation is critical.

Documented Overdose Profile

Domain Description (Regulatory Basis)
Primary Toxicity Severe delayed hepatotoxicity (liver damage).
Symptom Onset Initial symptoms (nausea, vomiting, pallor, sweating) may be mild, non-specific, or entirely absent for the first 24 hours or longer post-ingestion.
High-Risk Exposure Ingestion of a single toxic dose or accidental accumulation from taking multiple different cold/pain/fever relief products that contain the same active substance.
Vulnerable Populations Patients with pre-existing liver conditions, malnutrition, or chronic excessive alcohol use may be at greater risk for severe hepatic injury.

When to Seek Emergency Medical Attention

Seek emergency medical attention immediately. You must call for urgent medical help even if you feel completely well and have no symptoms. Do not wait for symptoms to appear. The window for effective intervention, which includes the administration of a specific antidote, is time-sensitive. Treatment must be initiated as quickly as possible to prevent or minimize irreversible liver damage.

Therapeutic Uses of Brismucol

Quick Facts: Brismucol

  • Goal of Therapy: Supports the clearance of respiratory secretions.
  • Main Therapeutic Domain: Conditions characterized by abnormal or excessive mucus in the airways.
  • Usage: Used to assist in managing short-term and long-term pulmonary or airway conditions.
  • Benefit Profile: Contributes to easing breathing by helping to thin and clear mucus.

Brismucol is a medication used in the management of various respiratory conditions that involve the production of thick or excessive mucus in the airways and lungs. The core purpose of this therapy is to support the body’s natural process for removing these secretions.

In therapeutic contexts, Brismucol is indicated for secretolytic therapy in patients with acute and chronic bronchopulmonary diseases where the clearance of mucus is impaired. This includes providing assistance in managing symptoms associated with respiratory conditions where thick phlegm presents a challenge to the patient.

By supporting the thinning of secretions, the medication helps to facilitate their transport and removal from the respiratory tract, a process that may contribute to improving a patient's breathing comfort.

In specific formulations, Brismucol has also been authorized for use to relieve discomfort associated with a sore throat. Additionally, injectable formulations are sometimes employed in neonatal care to address certain breathing difficulties in premature babies and to support lung development. However, the primary and most frequent use remains in the context of improving the viscosity and transport of respiratory secretions to support symptom management.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Brismucol?

This section outlines the official eligibility restrictions for Brismucol, based on government regulatory documentation (e.g., SmPC).

Populations That Must NOT Use This Medicine (Contraindications)

Population/Condition Restriction Type
Hypersensitivity Absolute Contraindication
Active Gastroduodenal Ulcer Absolute Contraindication
Pregnancy (First Trimester) Contraindicated/Not Recommended

Individuals with a known hypersensitivity to the active substance (Ambroxol) or any other component in the medicine are strictly prohibited from use. The medicine is also contraindicated for use in patients with an active gastroduodenal ulcer and is advised to be avoided during the first trimester of pregnancy.

Populations Requiring Caution or Restricted Use

Population/Condition Restriction Detail
Severe Organ Impairment Requires dose adjustment or extended intervals
Compromised Airways Requires cautious use; risk of mucus obstruction
Breastfeeding Women Not recommended; medicine passes into breast milk

Use requires special caution for patients with severe renal or hepatic impairment, necessitating a dose reduction or extended dosing interval. Breastfeeding women are not recommended to use the medicine. Individuals with compromised airway motility (e.g., Primary Ciliary Dyskinesia) must also use the medicine with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Brismucol (Ambroxol hydrochloride) identifies specific interaction patterns, focusing on pharmacodynamic conflicts and pharmacokinetic changes to co-administered substances, as documented by national health authorities.

Interaction Restrictions and Outcomes

Interaction Type Interacting Substance/Class Official Outcome/Restriction
Pharmacodynamic Restriction Cough Suppressants (Antitussive Agents) Co-administration is formally prohibited due to the risk of serious obstruction of the airways.
Pharmacokinetic Modification Antibiotics (Amoxicillin, Cefuroxime, Erythromycin, Doxycycline) Co-administration increases the concentration of these antibiotics in bronchopulmonary secretions.

Population-Specific Pharmacokinetic Caution

Population-specific cautions related to the clearance of the active substance or its metabolites are documented. In cases of severe renal insufficiency, the accumulation of hepatic metabolites is expected due to impaired elimination. Similarly, patients with severe hepatic impairment exhibit decreased elimination, leading to a measurable reduction in drug clearance. Official labeling contains no documentation of clinically significant metabolic (CYP enzyme) or transporter-mediated interactions with other drugs, nor are there any mandatory timing or separation requirements for administration.

Mechanism of Action

How Brismucol Works: Mechanism of Action

Brismucol's mechanism of action involves targeted antagonism of muscarinic acetylcholine receptors ( mAChRs), primarily the M3 subtype, located on the smooth muscle of the airways. By selectively binding to these receptors, Brismucol competitively prevents the binding of the endogenous neurotransmitter, acetylcholine ( ACh).

This blockade interrupts the parasympathetic nervous system's cholinergic signaling, specifically inhibiting the Gq-coupled intracellular cascade that drives muscle contraction. The physiological consequence of this pathway interruption is the relaxation of the bronchial smooth muscle, a process known as bronchodilation. This effect modulates airway muscle tone, increasing the physical size of the air passages and reducing resistance to airflow.

Furthermore, M3 receptor antagonism on submucosal glands results in the limitation of mucous secretion, which contributes to the overall physiological effect of reduced airway obstruction.

Dosage and Administration Information

Administration Guidelines

Brismucol (Ambroxol hydrochloride) is administered according to standardized regimens. The method and frequency of use are defined by the pharmaceutical form prescribed.

Approved Administration Routes and Forms

Administration is predominantly oral, involving tablets, syrups, or prolonged-release capsules. Specialized formulations also exist for inhalation (nebulized solution) and for specific hospital settings where the intravenous (IV) route may be utilized. Topical administration via lozenge is also available for localized use in the oral cavity. Oral doses should be taken with plenty of water and are typically advised to be consumed after a meal.

Standardized Dosing and Frequency

Form Type Standard Adult Dose Frequency Special Instructions
Immediate-Release (IR) 30 mg Two to three times daily (BID-TID) Total daily dose should not exceed 120 mg
Prolonged-Release (PR) 75 mg Once daily (QD) Must be swallowed whole; do not chew or crush

High-Level Use Constraints

Dosing for pediatric patients is adjusted based on age and weight, typically using liquid forms for precision. For patients with severe hepatic or renal impairment, prescribing information specifies that the dosage interval must be extended or the dose reduced. If a dose is missed, it is generally advised not to double the dose; instead, the missed dose should be skipped if it is near the time for the next scheduled dose. For self-care use, administration is typically limited to a short course of four to seven days.

Recent Clinical Evidence

Brismucol: Recent Clinical Evidence

Summary of Clinical Findings

Studies have evaluated whether the drug is associated with improved pain and function in participants with osteoarthritis (OA) and low back pain (LBP). The research included an evaluation of the drug’s profile in adult participants across various settings. Research has also explored the potential for relief of acute musculoskeletal pain.

One key meta-analysis examined the drug’s potential impact on chronic pain management. Findings were reported across different patient groups, including those with chronic musculoskeletal and post-operative pain. It is important to note that the overall evidence on long-term effects remains limited.

Detailed Study Outcomes

OA and LBP

Studies investigated whether the drug was associated with reduced pain and stiffness, and research has explored its comparative profile against older non-steroidal anti-inflammatory drugs (NSAIDs). Findings were mixed across different studies, with some reporting greater participant improvement and others reporting similar outcomes to comparator drugs. Multiple studies reported findings regarding inflammation markers and joint swelling.

Acute Pain Research

Research has investigated the combined use of the drug and physical therapy. The studies focused on whether this combination was associated with better short-term functional outcomes in patients recovering from soft-tissue injury. Studies have examined whether the mechanism of action is associated with changes in mobility.

Tolerability Profile

Research included assessments of tolerability across various dosing regimens in clinical trials.

Key Studies & References

  1. Efficacy of Thiocolchicoside for Musculoskeletal Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  2. A systematic review and network meta-analysis of pharmaceutical interventions used to manage chronic pain
  3. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials (Used for General Chronic Pain Context)

Frequently Asked Questions (FAQ)

Common questions about Brismucol (FAQ)

Q: What is Brismucol used for?

A: Brismucol is officially indicated for the treatment of certain chronic respiratory diseases. According to regulatory documents, it is used when there is thick mucus in the airways, and it is intended to help make the secretions less viscous.

Q: How does Brismucol work in the body?

A: Official product information states that Brismucol is a mucolytic agent. This means it works by chemically breaking down specific bonds within the thick mucus (sputum). This action reduces the viscosity (thickness) of the mucus, which helps the patient to clear it more easily.

Q: Is Brismucol safe to use during pregnancy?

A: Regulatory sources generally recommend caution regarding the use of Brismucol during pregnancy. Official product information advises that it should only be administered if the potential benefit justifies the potential risk to the fetus. Consulting a healthcare professional is recommended for those who are pregnant or planning to become pregnant, as its use is generally not recommended in the first trimester.

Q: Can Brismucol be used by children?

A: The official documentation indicates that Brismucol is approved for use in certain pediatric populations. However, the appropriate formulation and dosage depend on the child's age and specific condition. Official guidance indicates that dosing guidelines for children must be determined by a healthcare professional.

Q: Does Brismucol affect driving ability?

A: Studies and official information indicate that Brismucol is generally not expected to have a significant effect on the ability to drive or operate machinery. However, patients should be aware of possible side effects like dizziness, which could potentially impair these activities in rare cases. Should a patient experience such effects, caution regarding driving or operating machinery is generally advised.

Q: Is it safe to drink alcohol while taking Brismucol?

A: According to the official product information, there are no known direct negative interactions between Brismucol and alcohol. The product label does not specifically address interactions with alcohol, but general health guidelines often advise moderation with alcohol consumption while undergoing medication treatment.

Q: What should I do if I miss a dose of Brismucol?

A: Regulatory information on missed doses advises maintaining the treatment schedule by taking the next dose at the regularly scheduled time. The official documentation specifically states not to take a double dose to compensate for the missed dose.

Q: How long does it take for Brismucol to start working?

A: Official information indicates that the mucolytic effects may begin relatively quickly after administration. For managing chronic conditions, the full extent of the benefits may become noticeable after a consistent treatment period, often spanning several days or weeks.

How should Brismucol be stored and disposed of?

Storage and Disposal Requirements

Official regulatory information requires that Brismucol be stored under specific conditions to maintain its effectiveness and safety.

Requirement Category Official Regulatory Instruction
Storage Temperature Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). Do not freeze and avoid excessive heat.
Protection & Handling Keep the medicine in its original container, tightly closed. It must be protected from light and moisture to prevent degradation.
Child Protection Must be stored out of the sight and reach of children and pets.
Disposal Protocol Do not flush unused or expired product down the toilet or pour it down a drain, as this can contaminate the environment. Dispose of Brismucol through an authorized pharmaceutical take-back program at a local pharmacy or designated collection site.

These instructions define the mandatory environmental and handling constraints to ensure the product's stability throughout its labeled shelf-life. Disposal must follow established pharmaceutical-waste procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagColombia

flagEcuador

Equivalent of Brismucol found in:

A-Z Index: